确认宫内妊娠前药物流产:系统综述。

IF 1.9 3区 医学 Q3 OBSTETRICS & GYNECOLOGY Seminars in reproductive medicine Pub Date : 2022-11-01 DOI:10.1055/s-0042-1760117
Karin Brandell, John J Reynolds-Wright, Clare Boerma, Gillian Gibson, Helena Hognert, Heera Tuladhar, Oskari Heikinheimo, Sharon Cameron, Kristina Gemzell-Danielsson
{"title":"确认宫内妊娠前药物流产:系统综述。","authors":"Karin Brandell,&nbsp;John J Reynolds-Wright,&nbsp;Clare Boerma,&nbsp;Gillian Gibson,&nbsp;Helena Hognert,&nbsp;Heera Tuladhar,&nbsp;Oskari Heikinheimo,&nbsp;Sharon Cameron,&nbsp;Kristina Gemzell-Danielsson","doi":"10.1055/s-0042-1760117","DOIUrl":null,"url":null,"abstract":"<p><p>\"Very early medical abortion\" (VEMA) refers to medical abortion (with mifepristone and misoprostol) before intrauterine pregnancy is visualized on ultrasound. Our aim is to present the current evidence on efficacy, safety (focused on ectopic pregnancies), and how to assess treatment success of VEMA. We conducted a systematic review of studies reporting outcomes of VEMA. The field is small and so our objective was to map all relevant literature, without conducting meta-analysis. We searched PubMed, Medline, and Embase on April 19, 2022. We conducted a narrative synthesis of the evidence. A total of 373 articles were identified. Six articles (representing four observational and one pilot trial) were included in the final review. Across all included studies, treatment efficacy ranged between 91 and 100%. Prevalence of ectopic pregnancy was low and very few cases (<i>n</i> = 2) of ruptures were reported. Most studies used serial serum human chorionic gonadotrophin (s-hCG) levels to determine success of abortion; one study used low sensitivity urine hCG. From the available evidence, VEMA appears to be efficacious and does not appear to cause harm to ectopic pregnancies. Treatment can be assessed with pre- and postabortion s-hCG. Good quality, randomized controlled trial evidence is needed to best inform practice.</p>","PeriodicalId":21661,"journal":{"name":"Seminars in reproductive medicine","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Medical Abortion before Confirmed Intrauterine Pregnancy: A Systematic Review.\",\"authors\":\"Karin Brandell,&nbsp;John J Reynolds-Wright,&nbsp;Clare Boerma,&nbsp;Gillian Gibson,&nbsp;Helena Hognert,&nbsp;Heera Tuladhar,&nbsp;Oskari Heikinheimo,&nbsp;Sharon Cameron,&nbsp;Kristina Gemzell-Danielsson\",\"doi\":\"10.1055/s-0042-1760117\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>\\\"Very early medical abortion\\\" (VEMA) refers to medical abortion (with mifepristone and misoprostol) before intrauterine pregnancy is visualized on ultrasound. Our aim is to present the current evidence on efficacy, safety (focused on ectopic pregnancies), and how to assess treatment success of VEMA. We conducted a systematic review of studies reporting outcomes of VEMA. The field is small and so our objective was to map all relevant literature, without conducting meta-analysis. We searched PubMed, Medline, and Embase on April 19, 2022. We conducted a narrative synthesis of the evidence. A total of 373 articles were identified. Six articles (representing four observational and one pilot trial) were included in the final review. Across all included studies, treatment efficacy ranged between 91 and 100%. Prevalence of ectopic pregnancy was low and very few cases (<i>n</i> = 2) of ruptures were reported. Most studies used serial serum human chorionic gonadotrophin (s-hCG) levels to determine success of abortion; one study used low sensitivity urine hCG. From the available evidence, VEMA appears to be efficacious and does not appear to cause harm to ectopic pregnancies. Treatment can be assessed with pre- and postabortion s-hCG. Good quality, randomized controlled trial evidence is needed to best inform practice.</p>\",\"PeriodicalId\":21661,\"journal\":{\"name\":\"Seminars in reproductive medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2022-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in reproductive medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1055/s-0042-1760117\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in reproductive medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/s-0042-1760117","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 1

摘要

“极早期药物流产”(VEMA)是指超声显示宫内妊娠前药物流产(米非司酮和米索前列醇联合用药)。我们的目的是介绍目前关于VEMA的有效性、安全性(重点是异位妊娠)以及如何评估VEMA治疗成功的证据。我们对报道VEMA结果的研究进行了系统回顾。该领域很小,因此我们的目标是绘制所有相关文献,而不进行荟萃分析。我们在2022年4月19日检索了PubMed, Medline和Embase。我们对证据进行了叙述综合。共鉴定出373件物品。6篇文章(代表4篇观察性试验和1篇试点试验)被纳入最终综述。在所有纳入的研究中,治疗效果在91%到100%之间。异位妊娠的发生率较低,报告的破裂病例极少(n = 2)。大多数研究使用连续血清人绒毛膜促性腺激素(s-hCG)水平来确定流产成功率;一项研究使用低敏感性尿hCG。从现有的证据来看,VEMA似乎是有效的,似乎不会对异位妊娠造成伤害。可以通过流产前和流产后的s-hCG来评估治疗。需要高质量的随机对照试验证据来为实践提供最佳信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Medical Abortion before Confirmed Intrauterine Pregnancy: A Systematic Review.

"Very early medical abortion" (VEMA) refers to medical abortion (with mifepristone and misoprostol) before intrauterine pregnancy is visualized on ultrasound. Our aim is to present the current evidence on efficacy, safety (focused on ectopic pregnancies), and how to assess treatment success of VEMA. We conducted a systematic review of studies reporting outcomes of VEMA. The field is small and so our objective was to map all relevant literature, without conducting meta-analysis. We searched PubMed, Medline, and Embase on April 19, 2022. We conducted a narrative synthesis of the evidence. A total of 373 articles were identified. Six articles (representing four observational and one pilot trial) were included in the final review. Across all included studies, treatment efficacy ranged between 91 and 100%. Prevalence of ectopic pregnancy was low and very few cases (n = 2) of ruptures were reported. Most studies used serial serum human chorionic gonadotrophin (s-hCG) levels to determine success of abortion; one study used low sensitivity urine hCG. From the available evidence, VEMA appears to be efficacious and does not appear to cause harm to ectopic pregnancies. Treatment can be assessed with pre- and postabortion s-hCG. Good quality, randomized controlled trial evidence is needed to best inform practice.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Seminars in reproductive medicine
Seminars in reproductive medicine 医学-妇产科学
CiteScore
5.80
自引率
0.00%
发文量
24
审稿时长
6-12 weeks
期刊介绍: Seminars in Reproductive Medicine is a bi-monthly topic driven review journal that provides in-depth coverage of important advances in the understanding of normal and disordered human reproductive function, as well as new diagnostic and interventional techniques. Seminars in Reproductive Medicine offers an informed perspective on issues like male and female infertility, reproductive physiology, pharmacological hormonal manipulation, and state-of-the-art assisted reproductive technologies.
期刊最新文献
Current Ovulation and Luteal Phase Tracking Methods and Technologies for Fertility and Family Planning: A Review. Understanding the Strengths and Limitations of Online Oocyte Cryopreservation Calculators. Role of Anti-Müllerian Hormone in the Central Regulation of Fertility Preimplantation Genetic Testing for Polygenetic Conditions: A Legal, Ethical, and Scientific Challenge. Utility of Serum Anti-Müllerian Hormone Measurement as Part of Polycystic Ovary Syndrome Diagnosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1